


wherein:

- R^1 is H, OH, OMe, O-(C₁-C₃₀)-alkyl, O-aryl-(C₁-C₃₀)-alkyl, O-(C₂-C₃₀)-alkenyl, O-(C₃-C₃₀)-cycloalkyl or null and R^2 is H or OH, or R^1 , R^2 form together -O-,
 $R^3 = R^4 = \text{OMe}$ or R^3 and R^4 form together -OCH₂O-,
- n is 0 to 8,
- R^5 is H, OH, OMe, O-(C₁-C₃₀)-alkyl, O-aryl-(C₁-C₃₀)-alkyl, O-(C₂-C₃₀)-alkenyl, O-(C₃-C₃₀)-cycloalkyl or O-aryl,
 $Z = \text{O}, \text{S}, \text{or NH}, \text{and}$




or Z-R⁸ is NR¹²R¹³, R¹² and R¹³ representing respectively R⁹ and R¹⁰,

R⁹, R¹⁰, R¹¹ are independently H, C₁-C₃₀ alkyl, C₃-C₃₀ cycloalkyl, aryl, aryl-(C₁-C₃₀)-alkyl, C₂-C₃₀ alkenyl, C₂-C₃₀ alkynyl, C₁-C₃₀ trihalogenoalkyl, C₁-C₃₀

alkylamino-(C₁-C₃₀)alkyl, C₁-C₃₀ dialkylamino(C₁-C₃₀)-alkyl, amino-(C₁-C₃₀)-alkyl,

or




where R¹⁴, R¹⁵, R¹⁶ are independently H, halogen, C₁-C₃₀ alkyl, C₃-C₃₀ cycloalkyl, aryl, aryl-(C₁-C₃₀)-alkyl, C₂-C₃₀ alkenyl or C₂-C₃₀ alkynyl, or C₁-C₃₀ trihalogenoalkyl, and m is 0 to 4,

each of these groups including or not heteroatom(s),


or salt or tautomeric form thereof.

21. (Amended) A method of treating leukemia comprising administering to a human patient in need of such treatment using a subcutaneous mode of administration a harringtonine having the formula




wherein:

- R^1 is H, OH, OMe, O-(C₁-C₃₀)-alkyl, O-aryl-(C₁-C₃₀)-alkyl, O-(C₂-C₃₀)-alkenyl, O-(C₃-C₃₀)-cycloalkyl or null and
 R^2 is H or OH, or R^1 , R^2 form together -O-,
 $R^3 = R^4 =$ OMe or R^3 and R^4 form together -OCH₂O-,
- n is 0 to 8,
- R^5 is H, OH, OMe, O-(C₁-C₃₀)-alkyl, O-aryl-(C₁-C₃₀)-alkyl, O-(C₂-C₃₀)-alkenyl, O-(C₃-C₃₀)-cycloalkyl or O-aryl,
 $Z =$ O, S, or NH, and



or $Z-R^8$ is $NR^{12}R^{13}$, R^{12} and R^{13} representing respectively R^9 and R^{10} ,

R^9 , R^{10} , R^{11} are independently H, C₁-C₃₀ alkyl, C₃-C₃₀ cycloalkyl, aryl, aryl-(C₁-C₃₀)-alkyl, C₂-C₃₀ alkenyl, C₂-C₃₀ alkynyl, C₁-C₃₀ trihalogenoalkyl, C₁-C₃₀ alkylamino-(C₁-C₃₀)-alkyl, C₁-C₃₀ dialkylamino-(C₁-C₃₀)-alkyl, amino-(C₁-C₃₀)-alkyl,
or



where R^{14} , R^{15} , R^{16} are independently H, halogen, C_1 - C_{30} alkyl, C_3 - C_{30} cycloalkyl, aryl, aryl- $(C_1$ - $C_{30})$ -alkyl, C_2 - C_{30} alkenyl or C_2 - C_{30} alkynyl, or C_1 - C_{30} trihalogenoalkyl, and m is 0 to 4,


each of these groups optionally including heteroatom(s),

or salt or tautomeric form thereof,

wherein said harringtonine is in a formulation in which


- (i) the pH of the formulation is between 5.5 and 8.5,
- (ii) the harringtonines are in solution or hydrophilic freeze-dried powder ready-to-reconstitute of buffered salt of homoharringtonine or harringtonine, and
- (iii) the level of chromatographic purity of harringtonine is higher than 99.7%.

28. (Amended) A method of treating leukemia comprising administering to a human patient in need of such treatment using a subcutaneous mode of administration a harringtonine salt or tautomeric form thereof, wherein the harringtonine has the formula




wherein:

- R^1 is H, OH, OMe, O-(C₁-C₃₀)-alkyl, O-aryl-(C₁-C₃₀)-alkyl, O-(C₂-C₃₀)-alkenyl, O-(C₃-C₃₀)-cycloalkyl or null and
 R^2 is H or OH, or R^1 , R^2 form together -O-,
 $R^3 = R^4 =$ OMe or R^3 and R^4 form together -OCH₂O-,
- n is 0 to 8,
- R^5 is H, OH, OMe, O-(C₁-C₃₀)-alkyl, O-aryl-(C₁-C₃₀)-alkyl, O-(C₂-C₃₀)-alkenyl, O-(C₃-C₃₀)-cycloalkyl or O-aryl,
Z = O, S, or NH, and



or Z- R^8 is NR¹²R¹³, R¹² and R¹³ representing respectively R⁹ and R¹⁰,

R⁹, R¹⁰, R¹¹ are independently H, C₁-C₃₀ alkyl, C₃-C₃₀ cycloalkyl, aryl, aryl-(C₁-C₃₀)-alkyl, C₂-C₃₀ alkenyl, C₂-C₃₀ alkynyl, C₁-C₃₀ trihalogenoalkyl, C₁-C₃₀ alkylamino-(C₁-C₃₀)-alkyl, C₁-C₃₀ dialkylamino-(C₁-C₃₀)-alkyl, or amino-(C₁-C₃₀)-alkyl, or



C3 cont

where R^{14} , R^{15} , R^{16} are independently H, halogen, C_1 - C_{30} alkyl, C_3 - C_{30} cycloalkyl, aryl, aryl- $(C_1$ - $C_{30})$ -alkyl, C_2 - C_{30} alkenyl or C_2 - C_{30} alkynyl, C_1 - C_{30} trihalogenoalkyl, m is 0 to 4,

each of these groups optionally including heteroatom(s),

wherein said harringtonine is in a formulation in which

- (i) the pH of the formulation is between 5.5 and 8.5,
- (ii) the harringtonines are in solution or hydrophilic freeze-dried powder ready-to-reconstitute of buffered salt of homoharringtonine or harringtonine, and
- (iii) the level of chromatographic purity of harringtonine is higher than 99.7%.

C3ent